Abstract
Nitric oxide (NO) is produced in almost all tissues and it exerts a variety of biological actions under both physiological and pathological conditions. It is synthesized by three distinct enzymes: endothelial (eNOS), neuronal (nNOS) and inducible (iNOS) nitric oxide synthases. NO is a cardioprotective mediator in powerful cardioprotective processes such as pre- and post-conditioning ischemia; they operate largely in a NO-dependent manner. However, the activity of different NOSs isoforms as well as, the bioavailability of NO can be affected by a variety of disease conditions (in particular diabetes) and pathological situations associated with significantly elevated levels of the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α). These adversely affect NO-signaling, as well as the efficacy and safety of treatments with NO or NO-containing agents.
This brief review focuses on the role of NO in ischemic myocardial protection with emphasis on its contribution to ischemic pre-and post-conditioning cardioprotection. The impact of pathologic conditions on NO bioavailability and NO-signaling and its potential means for improvement, will also be discussed.
Keywords: Nitric oxide, cardiac ischemia, synthesized, endothelial, neuronal, cardioprotective, necrosis, myocardial, potential, tetrahydrobiopterin, reoxygenationinduced, atherosclerosis, PATHOGENESIS, exogenous, nitroglycerin
Current Pharmaceutical Design
Title: Nitric Oxide and Protection against Cardiac Ischemia
Volume: 17 Issue: 18
Author(s): Zhengyuan Xia and Paul M. Vanhoutte
Affiliation:
Keywords: Nitric oxide, cardiac ischemia, synthesized, endothelial, neuronal, cardioprotective, necrosis, myocardial, potential, tetrahydrobiopterin, reoxygenationinduced, atherosclerosis, PATHOGENESIS, exogenous, nitroglycerin
Abstract: Nitric oxide (NO) is produced in almost all tissues and it exerts a variety of biological actions under both physiological and pathological conditions. It is synthesized by three distinct enzymes: endothelial (eNOS), neuronal (nNOS) and inducible (iNOS) nitric oxide synthases. NO is a cardioprotective mediator in powerful cardioprotective processes such as pre- and post-conditioning ischemia; they operate largely in a NO-dependent manner. However, the activity of different NOSs isoforms as well as, the bioavailability of NO can be affected by a variety of disease conditions (in particular diabetes) and pathological situations associated with significantly elevated levels of the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α). These adversely affect NO-signaling, as well as the efficacy and safety of treatments with NO or NO-containing agents.
This brief review focuses on the role of NO in ischemic myocardial protection with emphasis on its contribution to ischemic pre-and post-conditioning cardioprotection. The impact of pathologic conditions on NO bioavailability and NO-signaling and its potential means for improvement, will also be discussed.
Export Options
About this article
Cite this article as:
Xia Zhengyuan and M. Vanhoutte Paul, Nitric Oxide and Protection against Cardiac Ischemia, Current Pharmaceutical Design 2011; 17 (18) . https://dx.doi.org/10.2174/138161211796391047
DOI https://dx.doi.org/10.2174/138161211796391047 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets The Determinants of Chagas Disease: Connecting Parasite and Host Genetics
Current Molecular Medicine Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Current Developments on Synthesis, Redox Reactions and Biochemical Studies of Selenium Antioxidants
Current Chemical Biology Role of PI3 Kinase Gamma in Excitation-Contraction Coupling and Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences
Current Pharmaceutical Design Application of Current Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy in Every Day Clinical Practice
Current Pharmaceutical Design Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management
Current Pharmaceutical Design Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry NADPH Oxidases in the Heart
Current Cardiology Reviews Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure
Current Vascular Pharmacology Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Current Pharmaceutical Biotechnology